middle.news
Noxopharm’s SOF-SKN™ Clears Crucial Safety Hurdles Ahead of HERACLES Trial
5:43pm on Sunday 1st of June, 2025 AEST
•
Biotechnology
Read Story
Noxopharm’s SOF-SKN™ Clears Crucial Safety Hurdles Ahead of HERACLES Trial
5:43pm on Sunday 1st of June, 2025 AEST
Key Points
SOF-SKN™ passed four stringent in vitro safety studies
Tests included genotoxicity, cardiac toxicity, and UV exposure assessments
Studies conducted under international Good Laboratory Practice standards
Final in vivo safety study underway to complete clinical trial requirements
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Noxopharm (ASX:NOX)
OPEN ARTICLE